Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

A Phase II, Randomized, Double-Blind Study of the Use of Rucaparib vs. Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

This study seeks to determine the effectiveness of Rucaparib as maintenance therapy for metastatic and recurrent endometrial cancer, after 1-2 prior lines of therapy.

Study Overview

• Status: Completed
• Conditions: Metastatic Endometrial Cancer
• Intervention / Treatment: Drug: Rucaparib; Drug: Placebo Oral Tablet

Detailed Description

This is a phase II clinical trial, that administers a maintenance treatment after first line chemotherapy is complete. It is designed to have a 1:1 randomization technique. Half the participants who enter the study will receive the active ingredient, Rucaparib, while the other half will receive a placebo. Treatment will be until progression with follow up until death.

• Study Type: Interventional
• Enrollment (Actual): 79
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Colorado
    • Aurora, Colorado, United States, 80045
      • University of Colorado Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 89 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Provision to sign and date the consent form.
2. Stated willingness to comply with all study procedures and be available for the duration of the study.
3. Be a female aged 18-89.
4. Patients with a primary Stage III/IV or recurrent endometrial cancer.
5. Patients have received at least one prior chemotherapy regimen and no more than two prior cytotoxic regimens (including hormonal therapy).
6. Primary chemotherapy regimen must have consisted of at least 4 completed cycles and no more than 8 completed cycles.
7. Previous cytotoxic regimen at least 4 weeks before initiation and no more than 8 weeks from initiation after last dose of previous therapy.
8. Patients who receive radiation to the whole pelvis or at least 50% of the spine must complete radiation therapy and have at least 4 weeks' time elapse prior to initiation of drug.
9. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
10. Absolute neutrophil count (ANC) > or = 1500 cells/microliters
11. Platelet count > 100,000 microliters
12. Hemoglobin > or = 9.0 g/dL
13. Serum albumin > or = 2.5 g/dL
14. Total bilirubin ≤ 1.5 x ULN (uppler limit of normal)
15. AST and ALT ≤ 3.0 x ULN
16. Serum Creatinine ≤ 1.5x ULN

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Inability to comply with study and follow-up procedures
2. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the past 3 months, unstable arrhythmias, or unstable angina
3. Known clinically significant liver disease defined as AST and ALT > 3.0 x ULN and/or Total bilirubin > or = 1.5 x ULN, or documented history of active viral, alcoholic, or other hepatitis, cirrhosis, and inherited liver disease
4. Participation in investigational clinical trial within last 30 days
5. History of significant chronic disease including HIV/AIDS or hepatitis C
6. Inability to provide informed consent
7. Known central nervous system (CNS) malignancy or CNS metastases
8. Patients with previous malignancy, other than endometrial, within the past 2 years from cycle 1, day 1, with the exception of those with negligible risk of metastasis or death, such as adequately controlled basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the breast.
9. History of stroke or transient ischemic attack (TIA) within 3 months prior to cycle 1 day 1(C1D1)
10. Women with prognosis for survival less than 6 months
11. Patients who have progressed or have stable disease (SD) through most recent chemotherapy regimen
12. Patients deemed otherwise clinically unfit for clinical trial per Investigator's discretion
13. Patients with duodenal stent or other GI disorder/defect that would interfere with absorption of oral medication
14. Female patients who maintain fertility potential and refuse to comply to use contraception and be followed for pregnancy by pregnancy testing
15. Minor surgical procedure < or = 14 days or major surgeries < or = 28 days prior to first dose of treatment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Active Ingredient; 1:1 Randomization. Participants in this arm receive the active ingredient medication.	Drug: Rucaparib; Participants allocated to the active ingredient arm will receive Rucaparib twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Medication should be taken around the same time every day, with 8 or more ounces of water.
Placebo Comparator: Placebo; 1:1 Randomization. Participants in this arm receive the placebo medication. (Placebos do not contain active ingredients).	Drug: Placebo Oral Tablet; Participants allocated to the placebo arm will receive a placebo tablet (that looks identical to the active ingredient tablet) twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Tablet should be taken around the same time every day, with 8 or more ounces of water.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival (PFS)	Progression free survival is defined as cycle 1 day 1 (C1D1) till the time of progression as determined by RECIST 1.1 criteria or death.	Up to 48 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS)	Overall survival is defined as cycle 1 day 1 (C1D1) till the time of death.	Up to 48 months.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Safety and tolerability analysis of Rucaparib will be summarized by dose and severity as assessed by the Common Toxicity Criteria for Adverse Events (CTCAE) version 5 and relationship to study drug.	Up to 48 months.

Collaborators and Investigators

• Sponsor: University of Colorado, Denver
• Collaborators: National Cancer Institute (NCI); Clovis Oncology, Inc.
• Investigators: Principal Investigator: Bradley Corr, MD, University of Colorado, Denver

Publications and helpful links

General Publications

• Corr BR, Haggerty A, Gysler SM, Taylor S, Behbakht K, Alldredge J, Lefkowits C, Brubaker LW, Bouts C, Babayan LM, Martin LP, Costello J, Bitler BG, Hu J, Guntupalli SR. A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. Gynecol Oncol. 2025 Sep;200:58-67. doi: 10.1016/j.ygyno.2025.07.008. Epub 2025 Jul 22.

Study record dates

Study Major Dates

• Study Start (Actual): March 6, 2019
• Primary Completion (Actual): October 31, 2023
• Study Completion (Actual): February 27, 2026

Study Registration Dates

• First Submitted: July 17, 2018
• First Submitted That Met QC Criteria: July 31, 2018
• First Posted (Actual): August 6, 2018

Study Record Updates

• Last Update Posted (Actual): March 24, 2026
• Last Update Submitted That Met QC Criteria: March 3, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Randomized; Double Blind; Placebo; Rucaparib; Stage III/IV
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Uterine Diseases; Genital Diseases, Female; Genital Neoplasms, Female; Uterine Neoplasms; Endometrial Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Antineoplastic Agents; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; rucaparib
• Other Study ID Numbers: 18-0567.cc; P30CA046934 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No